Trupanion, Inc., a Seattle-based financial services company specializing in pet health insurance, has reported recent changes regarding its common stock ownership and executive compensation. According to a recent 13-F filing, the company has implemented new equity awards for key executives alongside significant share divestment by a member of the board of directors.

The filing details the award of restricted stock units (RSUs) to the company’s Chief Marketing Officer. These units are scheduled to vest on a quarterly basis over a four-year period and are set to convert into ordinary shares at a one-for-one ratio.

Concurrently, a director of the board executed the sale of a substantial block of common shares. This divestment was conducted through two separate transactions, with the average sale price recorded in the mid-thirties per share. While these movements indicate active management involvement in equity compensation and secondary market activity, the filing notes that there has been no significant change to the company’s overall share structure.

Trupanion, Inc. operates within the insurance industry, providing medical insurance for dogs and cats across the United States, Canada, and Puerto Rico. The company has been publicly traded on the Nasdaq exchange since its initial public offering on July 18, 2014.

As of the market close on November 16, 2026, Trupanion, Inc. held a market capitalization of 1,570,000,000 USD, with a closing price of 36.55 USD. The company’s 52-week trading range has fluctuated between a low of 21.16 USD on May 20, 2026, and a high of 38.87 USD on November 5, 2026. The company currently maintains a price-to-earnings ratio of 58.76.